Natera reports record MRD testing growth and strong pipeline signal
The company says Q2 sales nearly 40% higher, with record Signatera volumes supported by MRD adoption and expanding clinical evidence.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.